Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment
Jungmin Lee, Christina M. Annunziata, John L. Hays, Liang Cao, Peter L. Choyke, Minshu Yu, Daniel An, Ismail Baris Turkbey, Lori M. Minasian, Seth M. Steinberg, Helen Chen, John Wright, Elise C. Kohn
Topics & Concepts
BevacizumabMedicineSorafenibInternal medicineClinical endpointOvarian cancerOncologyPhases of clinical researchAdverse effectGastroenterologyClinical trialSurgeryCancerHepatocellular carcinomaChemotherapyOvarian cancer diagnosis and treatmentAngiogenesis and VEGF in CancerPARP inhibition in cancer therapy